FUSE-AI
FUSE-AI GmbH is a medical technology company specializing in artificial intelligence solutions for radiology, particularly in cancer diagnostics using MRI data. Their flagship product, Prostate.Carcinoma.ai, is an AI plug-in integrated into existing PACS software to assist radiologists in prostate cancer diagnosis by automating and enhancing MRI analysis based on PI-RADS v2.1 guidelines. The company leverages high-quality dual-source training data from annotated MRI scans and histopathological datasets to ensure accuracy. FUSE-AI aims to address the growing gap between increasing cancer cases and declining radiologist availability by providing seamless AI tools that integrate into radiologists' existing workflows, improving diagnostic quality and efficiency. They also offer additional AI health services for medical, medtech, and pharmaceutical companies, focusing on enhancing efficiency and predictive capabilities in healthcare. The company is based in Hamburg, Germany, and actively participates in international healthcare and AI conferences, demonstrating strong industry engagement and growth potential.
FUSE-AI
FUSE-AI GmbH is a medical technology company specializing in artificial intelligence solutions for radiology, particularly in cancer diagnostics using MRI data. Their flagship product, Prostate.Carcinoma.ai, is an AI plug-in integrated into existing PACS software to assist radiologists in prostate cancer diagnosis by automating and enhancing MRI analysis based on PI-RADS v2.1 guidelines. The company leverages high-quality dual-source training data from annotated MRI scans and histopathological datasets to ensure accuracy. FUSE-AI aims to address the growing gap between increasing cancer cases and declining radiologist availability by providing seamless AI tools that integrate into radiologists' existing workflows, improving diagnostic quality and efficiency. They also offer additional AI health services for medical, medtech, and pharmaceutical companies, focusing on enhancing efficiency and predictive capabilities in healthcare. The company is based in Hamburg, Germany, and actively participates in international healthcare and AI conferences, demonstrating strong industry engagement and growth potential.
TL;DR
Founded: 2019
Focus: Medical AI for radiology (prostate MRI analysis)
Flagship product: Prostate.Carcinoma.ai (EU MDR 2017/745 Class IIa certified Dec 2023; marketed from Jan 2024)
Recent funding: €1.9M non-repayable project grant (KIROS, decision Feb 18, 2025)
Headquarters: Hamburg, Germany (operating entity); also lists an entity in Zürich, Switzerland